Share

    


Home / Search Results

Search Results

You searched for:

    Displaying results 1 - 20 of 25
  • 1
  • 2
  • »
If you are looking for legislative action, look no further than your state's legislatures. Most—if not all—states have had issues relating to oncology care and healthcare in general come up during their 2023 sessions.
For 2023, ACCC members have identified four core areas of focus (e.g., reimbursement, utilization management, provider-patient choice), among a larger set of issues and concerns, that the association will be supporting this year.
Dr. Barbara Schmidtman highlights key findings from the 2022 ACCC Mini Z burnout survey, comparing results from the pre-pandemic 2019 to now.
The ACCC 39th National Oncology Conference opened with two pre-conferences, covering financial advocacy in oncology and the future of cancer care. Learn what care delivery may look like in 2040 and how ACCC is supporting cancer programs and practices through its Financial Advocacy Network.
Dr. David Eagle shares why grassroot advocacy efforts are so important to furthering health equity and person-centered care in oncology, including how state-based efforts curbed harmful pharmacy benefit manager practices in New York.
ACCC Director Cancer Care Delivery and Health Policy Matt Devino, MPH, lays out the four key differences between the OCM and EOM that interested applicants need to consider.
Advocating on behalf of their patients and programs, ACCC members from 14 states participated in Virtual Hill Day, speaking with Congress and their staff on key legislation asks regarding access to care, telehealth, prior authorizations, and more.
ACCC has partnered with several of its oncology state societies to establish the Appalachian Community Cancer Alliance—a key effort to address disparities in cancer screening and care delivery in the region.
ACCC Board Member Wendi Waugh tells ACCCBuzz about her experience speaking at and attending the in-person Oncology Reimbursement Meetings this spring, covering topics from financial advocacy in oncology to formulary management and networking with colleagues to address workforce concerns at your cancer center.
ACCC is supporting the Improving Seniors’ Timely Access to Care Act of 2021, which would require Medicare Advantage plans to standardize and streamline prior authorization processes and increase the transparency of their requirements to prevent unnecessary denials and delays in patient care.
Jeanie Troy, a financial navigator at Lake Region Healthcare in the Cancer Care and Research Center, discusses how to help uninsured patients access their anti-cancer treatment if they are not eligible for Medicare or Medicaid.
After convening its members, sponsors, and industry partners in Washington, DC, for the first time since the dawn of COVID-19, ACCC Buzz shares a glimpse of the activities and insights the final day at ACCC’s 48th Annual Meeting and Cancer Center Business Summit.
As we approach the end of 2021, ACCCBuzz is recognizing the individuals who have been featured in our Financial Advocate Spotlights and the incredible stories they have shared with us.
As we turn the corner toward 2022, for oncology to drive equity forward: We need every member and every discipline, patient, leader, payer, industry partner, and innovator working together to provide the most equitable care possible in a sustainable way.
Put yourself first: this mantra is especially important today as we continue to grapple with the implications and fallout from the COVID-19 global pandemic.
In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
ACCC has long highlighted the racial and ethnic disparities that exist in oncology and hematology care delivery to advocate for true health equity for all patients with cancer. Through various programs, ACCC helps teach members of the multidisciplinary cancer care team how they can help patients overcome barriers and disparities in various treatment settings.
With total spending on U.S. cancer care projected to rise 34 percent from 2015-2030 to $245 billion, biosimilars can play a role in helping reduce those costs. Learn how Biden’s executive order on promoting competition in the American economy will require the FDA's biosimilars approval framework to be clearer and easier to follow.
On June 1, 2021, the Governor of Louisiana signed legislation that banned “white bagging” in the state, ensuring that health insurers cannot refuse to pay for approved physician-administered drugs and related services to covered patients. It is the first such law in the United States.
“For me, this experience was excellent, and I felt prepared with the preparation ACCC offered,” said Jared Kast, RT(T), MHA. The successful ACCC Virtual Hill Day—held May 12, 2021—brought together ACCC members and state lawmakers. Learn more about what issues were discussed and members' experiences in this new virtual format.
    Displaying results 1 - 20 of 25
  • 1
  • 2
  • »